PTAB Remains Unwilling to Deny Inter Partes Review Based on a Contractual Forum-Selection Clause

Nov 16, 2020

Reading Time : 2 min

The contract at issue was a nondisclosure agreement (NDA) that the parties had entered into “for the purpose of sharing confidential information to further [their] business relationship,” including information related to the patent owner’s proprietary technology. The NDA contained a forum selection clause under which the parties “agreed to resolve any disputes regarding the NDA and ‘the transactions contemplated hereby’ . . . in ‘a court of competent jurisdiction, federal or state, located within the Borough of Manhattan, City of New York.’” After the parties’ dealings eventually fell apart, the patent owner sued the petitioner for infringement and breach of contract in New York federal court. The petitioner countered by seeking an IPR on one of the allegedly infringed patents.

Invoking the NDA’s forum selection clause, the patent owner argued that contractual estoppel barred the petition, and it asked the board to deny institution under § 314(a), which allows discretionary denials where the information presented shows that the petitioner lacks a “reasonable likelihood” of success. The patent owner asserted that, although the board previously had rejected similar arguments, it had never “considered whether it may take into account such forum selection clauses under its plenary, discretionary authority . . . to decide when to institute IPR proceedings,” and that “the circumstances in this case warrant [it] doing so.”

In rejecting the patent owner’s contractual estoppel defense, the board first highlighted its prior decisions holding “that contractual estoppel is not a defense to inter partes review.” The board noted that some of those decisions even involved “contractual bar argument[s]” based on forum selection clauses specifically. As the board explained, it is not bound by such clauses and does not have “independent jurisdiction to resolve any contractual dispute” regarding them.

The board next reasoned that the relevant “equitable considerations” under § 314(a)—which include “factors related to . . . efficiency, fairness, and the merits”—did not justify a discretionary denial. The board emphasized that it could not, and would not, blindly accept that the district court in the parallel proceeding likely “would enjoin [the] Petitioner from participating in the IPR,” as the patent owner argued. Rather, the board would have to assess the merits of the patent owner’s estoppel defense, including by interpreting the forum selection clause “and the scope of the parties’ NDA under New York and 2nd Circuit law, as well as [the] Petitioner’s contentions to the contrary.” The board explained that making such determinations would be inconsistent with its prior decisions “expressly declining to consider forum selection clauses,” and that the equitable factors simply did not support denying the petition.

Practice Tip: The board’s ruling is a stark reminder that a contractual forum-selection clause, by itself, likely will not shield a patent owner from inter partes review. Patent owners should keep this in mind, not only when formulating their arguments for opposing an IPR petition, but also when drafting NDAs or other agreements with potential infringers. For instance, a patent owner should additionally consider negotiating for an express covenant not to challenge its patents before the Patent Office. The patent owner may then seek enforcement of such a covenant via injunctive relief in the agreed-upon forum.

 

Case: Samsung Elecs. Am, Inc. v. Kannuu Pty, Ltd., IPR2020-00738, Paper 22 (PTAB Sept. 23, 2020)

Share This Insight

Previous Entries

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.